Advertisement

Topics

Naurex Inc. Company Profile

14:49 EDT 22nd September 2017 | BioPortfolio

Naurex, Inc. is a private company developing novel therapies for depression and other CNS disorders based on the work of founder Dr. Joseph R. Moskal and colleagues now at The Falk Center for Molecular Therapeutics at Northwestern University, who discovered a new mechanism of action for modulating the NMDA receptor. Naurex has used these discoveries to generate novel chemical drug classes known as glycine site functional partial agonists (GFPAs). Naurex's first GFPA NMDA modulator, GLYX-13, has shown promising signs of antidepressant activity with excellent safety in preclinical studies. It is currently being assessed in a Phase I clinical trial in preparation for evaluation in patients with severe treatment-resistant depression. A second generation series of compounds is advancing rapidly in preclinical development.


News Articles [3 Associated News Articles listed on BioPortfolio]

Naurex's Novel Antidepressant GLYX-13 Recognized as One of Windhover's 2011 Top 10 Neuroscience Projects to Watch

EVANSTON, Ill., Nov. 7, 2011 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported t...

Eton Pharmaceuticals Appoints Dr. Norbert Riedel to its Board of Directors

DEER PARK, Ill., Sept. 7, 2017 /PRNewswire/ -- Eton Pharmaceuticals, Inc. today announced it has appointed Dr. Norbert Riedel, President and CEO of Aptinyx, to its Board of Directors. "We are pl...

Naurex Completes $38 Million Series B Financing

EVANSTON, Ill., Dec. 17, 2012 /PRNewswire/ -- Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the c...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [2 Associated Companies listed on BioPortfolio]

Naurex, Inc.

Naurex, Inc. is a private company developing novel therapies for depression and other CNS disorders based on the work of founder Dr. Joseph R. Moskal and colleagues who discovered a new mechanism of a...

Naurex Inc.

Naurex, Inc. is a private company developing novel therapies for depression and other CNS disorders based on the work of founder Dr. Joseph R. Moskal and colleagues now at The Falk Center for Molecula...

More Information about "Naurex Inc." on BioPortfolio

We have published hundreds of Naurex Inc. news stories on BioPortfolio along with dozens of Naurex Inc. Clinical Trials and PubMed Articles about Naurex Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Naurex Inc. Companies in our database. You can also find out about relevant Naurex Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Depression
Depression is a serious mental health condition, where sad feelings carry on for weeks or months and interfere with your life. The symptoms include feeling unhappy most of the time (but may feel a little better in the evenings), loosing interest in lif...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...


Corporate Database Quicklinks



Searches Linking to this Company Record